Original Article

Serology as a diagnostic tool for predicting initial *Pseudomonas aeruginosa* acquisition in children with cystic fibrosis☆,☆☆

Cori Daines [a,*], Donald VanDeVanter [b], Umer Khan [c], Julia Emerson [d], Sonya Heltshe [d], Sharon McNamara [d], Michael Anstead [e], Markus Langkamp [f], Gerd Doring [g,1], Felix Ratjen [h], Bonnie Ramsey [d], Ronald L. Gibson [d], Wayne Morgan [a], Margaret Rosenfeld [d] for the EPIC Investigators

[a] *University of Arizona, Tucson, AZ 85724, United States*
[b] *Case Western Reserve University School of Medicine, Cleveland, OH, United States*
[c] *Seattle Children's Research Institute, Seattle, WA 98121, United States*
[d] *Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA 98105-0371, United States*
[e] *Department of Pediatrics, University of Kentucky, Lexington, KY 40563-0284, United States*
[f] *Mediagnost®, Aspenhaustr. 25, 72770 Reutlingen, Germany*
[g] *Institute of Medical Microbiology and Hygiene, University of Tübingen, Tübingen, Germany*
[h] *Division of Respiratory Medicine, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada*

Abstract

Rationale: Pseudomonas aeruginosa (*Pa*) serology could potentially be a useful adjunct to respiratory culture methods for the detection of initial or early *Pa* infection in patients with cystic fibrosis (CF).

Objective: To evaluate the utility of *Pa* serology to predict *Pa* isolation from respiratory (generally oropharyngeal) cultures in the subsequent 6 or 12 months among young children with CF from whom *Pa* had never been previously cultured. *Pa* serology was also evaluated in a group of healthy controls.

Methods: Children ≤ 12 years of age without prior isolation of *Pa* from respiratory cultures participating in the Early Pseudomonal Infection Control EPIC Observational Study (EPIC OBS) had annual serum samples for measurement of antibodies against alkaline protease, elastase and exotoxin A using a commercial kit; controls had a single serum sample. Logistic regression with generalized estimating equations was used to characterize associations between $\log_{10}$ serum antibody titers and first isolation of *Pa* from a respiratory culture within the subsequent 6 or 12 months, with adjustment for sex and age. Receiver operating characteristic curves were used to optimize antibody titer cutpoints by age group. The diagnostic properties of each antibody were estimated using these optimized cutpoints.

Results: Pa serology was evaluated in 582 children with CF (2084 serum samples) and 94 healthy controls. There was substantial overlap between serum antibody titers among controls, CF patients who did not acquire *Pa* (N = 261) and CF patients who did acquire *Pa* (N = 321). The maximum positive predictive value for first *Pa* positive culture within the ensuing 6 months was 76.2% and maximum negative predictive value was 72.1% for any antigen or combination of antigens; values were similar for 12 months.

Conclusions: Pa serology does not appear useful for predicting first *Pa* positive oropharyngeal culture among young CF patients.

1. Introduction

Progressive obstructive lung disease due to chronic airway infection and inflammation is the leading cause of morbidity and mortality in cystic fibrosis (CF), with the bacterial pathogen *Pseudomonas aeruginosa* (*Pa*) playing a prominent role [1]. Initial *Pa* acquisition generally occurs in early childhood [2,3], but is often transient [2] and may be limited to the upper airways [4]. In contrast, approximately 80% of CF adults has chronic airway *Pa* infection [5], which is associated with more rapid lung function decline [3,6], increased morbidity [3,7] and decreased survival [8,9]. Today, children with CF are routinely treated with antipseudomonal antibiotics upon first *Pa* isolation in an attempt to eradicate the organism [10,11]. Eradication of early *Pa* infection has a roughly 80% success rate [11–13] and has been shown to reduce the prevalence of chronic *Pa* infection in CF cohorts compared to historical controls [14–16].

The accurate detection of early *Pa* infection is problematic, as young children and those with mild lung disease typically do not expectorate sputum. Surveillance respiratory cultures in these patients are typically performed on oropharyngeal (OP) swabs. While OP cultures are known to have imperfect diagnostic accuracy compared to lower airway cultures [4,17], they are nonetheless standard of care in the U.S. and many other countries, and are widely used to guide treatment decisions [18], define stages of *Pa* infection [19] and predict clinical outcomes [20,21].

Serum titers of antibodies against *Pa* antigens have been shown to be elevated in chronic *Pa* infection [22,23] and to distinguish intermittent from chronic *Pa* colonization [24,25]. However, as most chronically infected patients expectorate sputum, the clinical utility of serology in this context is limited. In contrast, it has been suggested that *Pa* serology could prove a useful adjunct to respiratory culture methods for the detection of initial or early *Pa* infection [24,26,27], as serology has the potential advantages of being more accurate than upper airway cultures and less resource-intensive and invasive than BAL. The diagnostic accuracy of *Pa* serology relative to concurrent respiratory cultures remains controversial [17,28–30].

Importantly, several studies have demonstrated that positive *Pa* serology may precede initial isolation of *Pa* from both upper [2,3,25,29,31] and lower [2] airway cultures. If positive *Pa* serology could predict subsequent isolation of *Pa* from respiratory cultures, eradication therapy could potentially be initiated at an earlier stage to improve outcomes; this has been advocated [24] but not yet investigated.

The Early Pseudomonas Infection Control Observational Study (EPIC OBS) is a U.S. national prospective study to evaluate the risk factors for and clinical outcomes associated with isolation of *Pa* from respiratory cultures in a large cohort of children with CF who were *Pa*-culture negative at enrollment [32]. The objective of the current analysis was to evaluate the utility of *Pa* serology to predict subsequent *Pa* isolation from respiratory (generally OP) culture among young children with CF from whom *Pa* had never been previously cultured. We hypothesized that *Pa* serology would have acceptable diagnostic accuracy in predicting first isolation of *Pa* from respiratory cultures within the ensuing 6 or 12 months. As part of the current analysis, we also examined *Pa* serology and OP cultures in a cohort of children without CF undergoing elective surgical procedures at a single institution to assess the levels of anti-*Pa* antibodies in the unaffected population. Portions of this work have previously been published in abstract form.

2. Methods

2.1. Study participants and samples

The design of the EPIC OBS has been reported elsewhere [33,34]. Children with an established diagnosis of CF [35] ≤ 12 years of age were enrolled at 59 accredited U.S. CF care centers between 2004 and 2006. Annual serum samples were collected for serology and banking, and the results of clinical respiratory cultures were recorded in the CFF National Patient Registry (CFFNPR). Eligibility criteria for participation in the current analysis were 1) no prior isolation of *Pa* from respiratory cultures since CF diagnosis, confirmed with CFFNPR data, 2) no loss to follow up or isolation of *Pa* from a respiratory culture in the first 120 days after enrollment [36] (as these individuals may have had had *Pa* infection prior to enrollment), and 3) at least one serum sample collected. Written informed consent was obtained from the family of each participant and the study was approved by the Institutional Review Board at each participating site. Serum samples collected through 2009 and data collected through 2010 were included in the current analysis.

2.2. Non-CF controls

Otherwise healthy children ≤ 18 years of age undergoing a clinically indicated procedure that required sedation or anesthesia at Seattle Children's Hospital, Seattle, WA, USA between September 2008 and February 2010 were recruited. Exclusion criteria included: (1) presence of indwelling catheters or devices (including myringotomy tubes) at enrollment or within the past year; (2) oral or IV antibiotic treatment within the past month; (3) presence of congenital or acquired immunosuppression; (4) history of cancer; (5) currently undergoing an otolaryngology or dental procedure; (6) immediate family member with CF; (7) blood transfusion within the past year. A serum sample for serology and an OP swab for culture were collected from each participant. The study was approved by the Seattle Children's

Hospital IRB and informed consent was obtained from all parents/guardians, as well as assent from participants as applicable. The respiratory culture results from this cohort have been previously published [34].

2.3. Pseudomonas serology

Serum samples were analyzed for titers of antibodies to the *Pa* antigens alkaline protease, exotoxin A, and elastase by Mediagnost® (Reutlingen, Germany) using their commercially available IgG enzyme immunoassay system [24,28,37]. Assays were batched and performed in duplicate. The lower limits of quantification were 0.41, 0.15 and 0.35 titer/ml for alkaline protease, exotoxin A and elastase, respectively (equal to 10 times the standard deviation of the blank). Intraassay variances were 4.39, 5.3 and 11.5% of the coefficient of variation (CV) and interassay variances were 5.7, 7.7 and 8.0% of the CV for alkaline protease, elastase and exotoxin A, respectively. The linearity of sample dilution has been proven for dilution range of 1:500 to 1:24,000 by the manufacturer. An independent evaluation of the test system has been conducted [24,28].

2.4. Statistical analyses

Logistic regression models were used to characterize associations between $\log_{10}$ serum antibody titers and first isolation of *Pa* from a respiratory culture within the subsequent 6 or 12 months, with generalized estimating equations (GEE) methods used to account for repeated observations per patient, and adjustment for sex, age (1–≤3 years, >3–≤6 years, >6 years) and time (days) between serum sample and respiratory culture. Receiver operating characteristic (ROC) curves were used to optimize antibody titer cutpoints to maximize the sensitivity and specificity of each antibody and by age group (0–<6 years, ≥6 years), using the area under the curve (AUC). The diagnostic properties of each serologic assay, including sensitivity, specificity, positive predictive value, and negative predictive value were estimated based on these optimized cutpoints. Similar analyses were performed for concurrent respiratory cultures (defined as collection within 3 weeks of the serum collection date) for comparison purposes. Analyses were performed using R version 2.15.1 (R Foundation for Statistical Computing, Vienna, Austria) and SAS, version 9.2 (SAS Institute Inc., Cary, NC).

3. Results

A total of 1797 children with CF were enrolled in EPIC OBS between 2004 and 2006, of which 687 had no isolation of *Pa* from respiratory cultures prior to or during the first 120 days after enrollment. Of these 687 children, 582 had at least one serum sample collected during the observation period and therefore comprise the cohort for the current analyses. These 582 children contributed 2084 serum samples; 261 children (44.8%) had a first *Pa*-positive respiratory culture during the observation period and 321 remained *Pa*-negative. At baseline (Table 1), participants who subsequently acquired *Pa* were similar to those who remained *Pa* negative with respect to age and sex, but the proportion of children

Table 1
Baseline characteristics of children with CF.

	Did not acquire *Pa* (N = 321)	Acquired *Pa* (N = 261)	Total (N = 582)
Age, years mean (SD)	5.0 (3.5)	5.5 (3.4)	4.8 (3.4)
Age distribution			
0–3 years, n (%)	114 (35.5%)	106 (40.6%)	220 (37.8%)
>3–6 years, n (%)	84 (26.2%)	66 (25.3%)	150 (25.8%)
>6–12 years, n (%)	123 (38.3%)	89 (34.1%)	212 (36.4%)
Male, n (%)	157 (48.9%)	127 (48.7%)	284 (48.8%)
CFTR functional class [a]			
High risk	210 (65.4%)	210 (85%)	420 (72.2%)
Low risk	53 (16.5%)	14 (5.4%)	67 (11.5%)
Not classified	51 (15.9%)	26 (10%)	77 (13.2%)
Missing	7 (2.2%)	11 (4.2%)	18 (3.1%)
Pancreatic sufficient [b]	73 (22.7%)	23 (8.8%)	96 (16.5%)

[a] High risk: both alleles with mutations in functional class 1, 2 or 3; low risk: at least one allele with a class 4 or 5 mutation; not classified: functional class not able to be determined based on mutations detected [46].
[b] Defined by pancreatic enzyme replacement therapy use in the CFF Registry.

with a high risk *CFTR* genotype was higher in participants who acquired *Pa* (85.0% versus 65.4%, P < .0001), as was the prevalence of pancreatic insufficiency (91.2% versus 77.3%, P < .0001). A serum sample for serology and a simultaneous OP swab for culture were collected from 94 non-CF controls, who had a mean (SD) age of 8.5 (5.4) years; 54 were male. *Pa* was isolated from only 1 of the 94 OP cultures.

3.1. Serum antibody titers and association with concurrent or subsequent Pa isolation from respiratory cultures

Among the 261 children with CF who acquired *Pa* during the observation period, 169 (64.8%) had serum samples collected within 6 months prior to *Pa* isolation and all had a serum sample within 12 months prior to *Pa* isolation. A total of 68 (26.1%) had serum samples collected concurrently with *Pa* isolation, with a median elapsed time between the recorded date of serum collection and respiratory sample collection of 0.0 day (mean = 0.94 day, SD = 3.86 days) for this group.

Alkaline protease titers tended to be higher in CF patients than in controls, though these titers did not distinguish between CF patients who remained *Pa* negative and those who acquired *Pa* (Fig. 1). Exotoxin A titers tended to be highest in CF patients who were concurrently *Pa* positive. In general, however, there was substantial overlap between titers of all three antigens across participant groups (Fig. 1).

Among the non-CF control children, 40%, 59% and 36%, respectively, had antibody titers below the limit of quantitation and 24%, 29%, and 16% had antibody titers ≥ 100 against alkaline protease, exotoxin A and elastase, respectively. Among 94 serum samples randomly selected from 94 age-matched CF children, 33%, 31% and 53%, respectively, had antibody titers below the limit of quantitation and 27%, 28%, and 21% had antibody titers ≥ 100 against alkaline protease, exotoxin A and elastase, respectively.

In logistic regression models, serum exotoxin A and elastase antibody titers, but *not* alkaline protease antibody titers, were

Fig. 1. Serum antibody titers in non-CF control children, children with CF that remained *Pa* negative for the subsequent year and children with CF that had initial isolation of *Pa* from a respiratory culture within the subsequent year. Box plots of serum titers of antibodies against *Pa* alkaline protease (left panel), exotoxin A (center panel), and elastase (right panel). Non-CF control children (hashed bars), children with CF that did not have *Pa* cultured in the subsequent year after serum collection (clear bars), and children with CF that had *Pa* cultured within the subsequent 12 months, 6 months, and concurrently with serum collection (gray bars) are shown. Sample sizes are shown above the bars. Medians, 25th and 75th percentiles and ranges are depicted.

statistically significant predictors of concurrent *Pa* isolation (P < .001), or *Pa* isolation within 6 months (P < .001) or 12 months (P ≤ .001) of serum collection among participants with CF, with odds ratios generally <2 (Fig. 2). Of the three *Pa* antigens, exotoxin A consistently had the largest effect size. Odds ratios decreased as the interval of time between serum collection and subsequent *Pa* isolation increased (Fig. 2).

ROC curve analyses and area under the curve (AUC) calculations for children with CF confirmed the relatively low diagnostic accuracy of antibody titers against all three antigens for predicting *Pa* isolation from respiratory cultures, with the highest AUC being 0.690 (a value of 0.5 indicates no association

between the diagnostic test and the outcome). The rank order of association between antibody titers and probability of subsequent *Pa* isolation was exotoxin A > elastase > alkaline protease, and the AUCs were highest for concurrent isolation of *Pa* (Fig. 3).

Based on the ROC curves in Fig. 3, antibody titer cutpoints of ≥ 100 were used to test the accuracy of seropositivity compared to concurrent and subsequent *Pa* isolation (Table 2). In addition to studying each antigen independently, the predictive ability of combinations of seropositivity for the three antigens was analyzed. The ability of positive serology to predict subsequent *Pa* isolation (positive predictive value, PPV) was generally poor, ranging from 34.1% (95% CI 26.0, 43.3) to 61.1% (95% CI 43.5, 76.4). The greatest PPV was achieved when all three antibody titers were positive, and the PPV increased with the length of time allowed after serum collection for detection of a positive culture. The latter finding is at least in part due to the fact that predictive values are influenced by prevalence (whereas sensitivity and specificity are not). The prevalence of isolation of *Pa* within 6 months and 12 months of serum sample collection were 34% and 45%, respectively. Among children with CF who had serum antibody titers ≥ 100 for all three *Pa* antigens, 56.2% went on to have *Pa* cultured within 6 months and 61.1% within a year.

The ability of negative serology to predict no subsequent isolation of *Pa* (negative predictive value, NPV) was better than the PPV, ranging from 54.4% (95% CI 49.6, 59.1) to 70.7% (95% CI 65.6, 75.4). The NPV of exotoxin A antibody titers < 100 was greater than that of other antibodies, either alone or in combination with exotoxin A. The NPV for serology decreased with increasing time from serum collection to culture, again, in part due to fact the predictive values are influenced by prevalence. For instance, only 70.7% of children with exotoxin A antibody titers <100 remained *Pa* negative for up to 6 months, and only 59.7% was *Pa* negative for up to a year after serum collection (Table 2).


Fig. 2. Odds ratios for the effect of $\log_{10}$ serum antibody titers on risk of concurrent *Pa* isolation and *Pa* isolation within 6 months and 12 months after serum collection in children with CF. A logistic regression model was adjusted for patient sex and age (1–≤3 years, >3–≤6 years, >6 years). Odds ratios (log scale) are shown for risk of concurrent *Pa* isolation (clear circles), *Pa* isolation within 6 months after serum collection (gray circles), and within 12 months (black circles) after serum collection. Bars represent 95% confidence intervals for odds ratios.

Fig. 3. ROC curves for serology as a predictor of subsequent *Pa* isolation in children with CF. Curves for alkaline protease (left), exotoxin A (center), and elastase (right) prediction of concurrent *Pa* isolation (black lines), within 6 months (gray lines), and within 12 months (hashed lines) of serum collection are shown. Antibody titers of 100 (open circles) are noted.

3.2. Effect of age-specific cutpoints

Serum antibody titers were generally lower in children with CF less than 6 years of age than in older children (Fig. 4—online supplement). Thus, we constructed ROC curves CF by age group (1 to <6 and ≥6 years old) (Fig. 4—online supplement). Using these data, optimal antibody titer cutpoints for each age group were determined using serum sample level modeling (Table 3—online supplement). Age-specific titer cutpoints improved the diagnostic properties of serologic assays for prediction of *Pa* isolation (Table 4—online supplement). For example, the best PPV for *Pa* isolation in the subsequent 6 months when titers for all three antibodies were ≥ 100 improved from 56.2% (CI 37.9, 73.2) (Table 2) to 76.2% (CI 52.5, 90.9) using age-specific cutpoints (Table 4—online supplement). Cutpoints optimized by

age produced a much smaller improvement in the NPV for *Pa* isolation in the subsequent 6 months, going from 67.8% (CI 61.8, 73.3) to 72.1% (CI 66.5, 77.1) for presence of ≥ 1 antibody above the cutpoint (Table 2 and online supplement Table 4). The highest positive and negative predictive values for concurrent *Pa* isolation and isolation in the subsequent 6 or 12 months using both sets of antibody titer cutpoints are shown in Fig. 5 (online supplement).

4. Discussion

Based on reports by our group [2] and others [31] that positive serology may precede first isolation of *Pa* from respiratory cultures, we aimed to assess whether *Pa* serology could accurately predict subsequent isolation of *Pa* from oropharyngeal cultures in

Table 2

Seropositivity (titers ≥ 100) as a predictor of concurrent or subsequent *Pa* isolation among children with CF.

	Individual *Pa* antigens with antibody titers ≥ 100			Number of *Pa* antigens with antibody titers ≥ 100		
	Alkaline protease	Exotoxin A	Elastase	≥ 1/3	≥ 2/3	3/3
Pa isolation concurrent with serum collection						
Sensitivity [a]	35.3 (24.4, 47.9)	54.4 (41.9, 66.4)	32.4 (21.8, 44.9)	66.2 (53.6, 76.9)	41.2 (29.6, 53.8)	14.7 (7.7, 25.8)
Specificity [b]	75.0 (69.8, 79.6)	75.9 (70.8, 80.5)	84.2 (79.6, 87.9)	55.7 (50.0, 61.2)	83.9 (79.2, 87.6)	95.6 (92.5, 97.5)
Positive predictive value [c]	23.3 (15.8, 32.9)	32.7 (24.4, 42.3)	30.6 (20.5, 42.7)	24.3 (18.5, 31.3)	35.4 (25.2, 47.1)	41.7 (22.8, 63.1)
Negative predictive value [d]	84.3 (79.4, 88.3)	88.6 (84.0, 92.0)	85.3 (80.7, 88.9)	88.4 (83.0, 92.4)	86.9 (82.5, 90.4)	83.9 (79.6, 87.4)
Pa isolation within 6 months after serum collection						
Sensitivity	24.9 (18.7, 32.2)	39.1 (31.7, 46.9)	23.7 (17.6, 30.9)	49.7 (42.0, 57.5)	27.2 (20.8, 34.7)	10.7 (6.6, 16.5)
Specificity	74.8 (69.6, 79.4)	77.6 (72.5, 81.9)	84.1 (79.5, 87.8)	55.8 (50.1, 61.2)	85.0 (80.6, 88.7)	95.6 (92.6, 97.5)
Positive predictive value	34.1 (26.0, 43.3)	47.8 (39.3, 56.5)	44.0 (33.7, 54.7)	37.2 (30.9, 43.9)	48.9 (38.6, 59.4)	56.2 (37.9, 73.2)
Negative predictive value	65.4 (60.3, 70.2)	70.7 (65.6, 75.4)	67.7 (62.8, 72.2)	67.8 (61.8, 73.3)	68.9 (64.1, 73.4)	67.0 (62.5, 71.3)
Pa isolation within 12 months after serum collection						
Sensitivity	23.0 (18.1, 28.7)	35.6 (29.9, 41.8)	19.2 (14.7, 24.6)	45.6 (39.5, 51.8)	23.8 (18.8, 29.5)	8.4 (5.5, 12.7)
Specificity	74.8 (69.6, 79.4)	77.6 (72.5, 81.9)	84.1 (79.5, 87.8)	55.8 (50.1, 61.2)	85.0 (80.6, 88.7)	95.6 (92.6, 97.5)
Positive predictive value	42.6 (34.4, 51.2)	56.4 (48.4, 64.0)	49.5 (39.5, 59.6)	45.6 (39.5, 51.8)	56.4 (46.6, 65.7)	61.1 (43.5, 76.4)
Negative predictive value	54.4 (49.6, 59.1)	59.7 (54.8, 60.6)	56.1 (51.6, 60.6)	55.8 (50.1, 61.2)	57.8 (53.2, 62.3)	56.2 (51.9, 60.4)

[a] Proportion of patients with antibody titers ≥ 100 among those who had subsequent *Pa* isolation with confidence intervals.
[b] Proportion of patients with antibody titers < 100 among those who remained culture negative with confidence intervals.
[c] Proportion of patients who had subsequent *Pa* isolation among those with antibody titers ≥ 100 with confidence intervals.
[d] Proportion of patients who remained culture negative among those with antibody titers <100 with confidence intervals.

a cohort of *Pa* negative patients. If so, routine surveillance of *Pa* serology might potentially allow for earlier detection of *Pa* infection and therefore earlier initiation of *Pa* eradication therapy, potentially improving outcomes. Unfortunately, we found that positive serology was not able to accurately predict isolation of *Pa* in the ensuing 6 or 12 months. In our cohort, even using antibody titer cutpoints optimized for age, the positive predictive value of *Pa* serology for predicting isolation of *Pa* from a respiratory culture in the ensuing 6 months was 76.2% and the negative predictive value was 72.1%. In other words, about 1 in 4 children predicted based on positive serology to become *Pa* positive in the next 6 months did not actually acquire *Pa* during that time period, while 1 in 4 children predicted by negative serology to remain *Pa* negative in the next 6 months in fact became *Pa* positive during the same period.

Isolation of new *Pa* from oropharyngeal cultures in children with CF is not a clinical endpoint, but rather an admittedly imperfect diagnostic test [4], and it seems clear that some of the inability of serology to predict subsequent *Pa* isolation in our study is a result of the limitations of our chosen "gold standard" rather than of *Pa* serology. Molecular methods for detection of *Pa* infection are gaining traction [24–27,31] and had we utilized such techniques, our outcomes may have been different. However, because treatment decisions in the U.S. are still generally made today based on *Pa* isolation from conventional upper airway cultures [18], we felt it was reasonable to test the ability of serology to act as a diagnostic surrogate for *Pa* isolation from these cultures. The presence of substantial titers of antibodies to *Pa* in children without CF (Fig. 1) and the relatively poor predictive power of optimized serology in children with CF (Fig. 5—online supplement) suggest that serology as we have studied it would not be a particularly useful diagnostic surrogate for upper airway culture. In addition, Douglas et al. [17] found very similar results to ours when comparing *Pa* serology to simultaneous lower airway cultures obtained by BAL. Whether or not intervening with anti-pseudomonal antibiotics when positive serology is first detected might improve outcomes is an entirely different question from the one we evaluated, one requiring a randomized, controlled trial in which clinical endpoints rather than surrogate outcomes such as oropharyngeal cultures are evaluated.

Though ours is the first study to evaluate the utility of *Pa* serology in predicting *subsequent* first isolation of *Pa* from respiratory cultures among *Pa* negative patients, several prospective studies have evaluated the diagnostic utility of serology compared to *concurrent* respiratory cultures in early *Pa* infection, with conflicting results. Douglas et al. [17], reported similarly low positive and negative predictive values of serology in young CF patients undergoing BAL. Others have reported higher diagnostic accuracy [29,30,38]. These differences can be attributed to the specific antigens evaluated, the choice of cutpoint for defining a positive titer, the prevalence of *Pa* in the population tested, and the source of respiratory cultures (sputum vs. oropharyngeal swabs vs. BAL) [25].

In the early development of ELISA assays for *Pa* antibodies, several investigators looked for serum *Pa* antibodies in non-CF children with no history of *Pa* infection [23,39–41]. To our knowledge, ours is the first study to evaluate *Pa* serology in non-CF control children in whom concurrent OP cultures were performed. Among the 94 control children in our study, in whom *Pa* was isolated from an OP culture in only one, there was nonetheless evidence of possible prior *Pa* infection based on *Pa* serologic titers >100. Interestingly, van Ewijk et al. [42] performed serial OP cultures in 20 children with CF and 19 unrelated healthy controls each time the children presented with signs and symptoms of a viral respiratory infection during one viral season, and isolated *Pa* from 37% of the controls and 30% of the children with CF. The *Pa* persisted in the children with CF whereas it was rapidly cleared from the control children. Thus, the respiratory tract may be a common site of *Pa* infection in healthy children. Other potential sources of mucosal invasion could include the skin, gastrointestinal or genitourinary tracts. Whether or not these healthy children truly had experienced *Pa* infection, the lack of specificity of *Pa* antibodies to children with CF is one reason why *Pa* serology may be less useful in detecting early *Pa* infection in children with CF.

Our study has several limitations in addition to sampling oropharyngeal swabs rather than BAL for assessment of respiratory cultures. First, serum for serology was only collected annually, so conclusions regarding more frequent sampling cannot be drawn. However, routine annual blood tests are standard of care in the U.S. Secondly, since positive and negative predictive values are affected by prevalence, the observation that PPV increases while NPV decreases with increased observation time after serum collection is in part due to the increased prevalence of *Pa*-positivity with increasing observation time. Similarly, our results should not be generalized to populations with widely different rates of *Pa* acquisition. Finally, we did not evaluate the effect of *Pa* eradication treatment on *Pa* serology, though Ratjen et al. [30] and Anstead et al. [37], have both demonstrated that *Pa* antibody titers may be useful in monitoring response to treatment. Finally, we chose to evaluate *Pa* serology using a commercial assay so that it could easily be adopted by clinical laboratories. We measured IgG antibodies to elastase, alkaline phosphatase and exotoxin A, as these antibodies have been extensively evaluated in CF [17,22,24,25,27–31,37]. Our results should not be generalized to serologic assays for antibodies to other antigens, other antibodies (i.e. IgM, IgA) to these antigens, or non-commercial kits for the antibodies we studied [43]. It is possible that serology to other antigens, such as flagellar antigens, might have yielded different results [44,45].

In conclusion, our results demonstrate that *Pa* serology is only modestly accurate in predicting subsequent first isolation of *Pa* from upper respiratory cultures among *Pa* negative CF patients. Thus, the role of *Pa* serology in the routine monitoring of early *Pa* infection remains unclear.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.jcf.2014.06.005.

References

[1] Doring G. Prevention of *Pseudomonas aeruginosa* infection in cystic fibrosis patients. Int J Med Microbiol 2010;300:573–7.

[2] Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, et al. Longitudinal assessment of *Pseudomonas aeruginosa* in young children with cystic fibrosis. J Infect Dis 2001;183:444–52.

[3] Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al. Longitudinal development of mucoid *Pseudomonas aeruginosa* infection and lung disease progression in children with cystic fibrosis. JAMA 2005;293:581–8.

[4] Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28:321–8.

[5] Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry. Annual Data Report; 2012 MD2013 [Bethesda].

[6] Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134–9 [9 e1].

[7] Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et al. Acceleration of lung disease in children with cystic fibrosis after *Pseudomonas aeruginosa* acquisition. Pediatr Pulmonol 2001;32:277–87.

[8] Henry RL, Mellis CM, Petrovic L. Mucoid *Pseudomonas aeruginosa* is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158–61.

[9] Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: *Pseudomonas aeruginosa* infection. J Clin Epidemiol 1995;48:1041–9.

[10] Starner TD, McCray Jr PB. Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med 2005;143:816–22.

[11] Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating *Pseudomonas aeruginosa* in people with cystic fibrosis. Cochrane Database Syst Rev 2009:CD004197.

[12] Ratjen F, Munck A, Kho P, Angyalosi G. Treatment of early *Pseudomonas aeruginosa* infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010;65:286–91.

[13] Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, et al. Comparative efficacy and safety of 4 randomized regimens to treat early *Pseudomonas aeruginosa* infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011;165:847–56.

[14] Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with *Pseudomonas aeruginosa* postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330–5.

[15] Hoiby N, Frederiksen B, Pressler T. Eradication of early *Pseudomonas aeruginosa* infection. J Cyst Fibros 2005;4(Suppl. 2):49–54.

[16] Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication therapy against *Pseudomonas aeruginosa* in cystic fibrosis patients. Eur Respir J 2005;26:458–61.

[17] Douglas TA, Brennan S, Berry L, Winfield K, Wainwright CE, Grimwood K, et al. Value of serology in predicting *Pseudomonas aeruginosa* infection in young children with cystic fibrosis. Thorax 2010;65:985–90.

[18] Saiman L, Cohen MB. What have we learned about early treatment of *Pseudomonas aeruginosa* infection in infants and children with cystic fibrosis? Arch Pediatr Adolesc Med 2011;165:867–8.

[19] Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic *Pseudomonas aeruginosa* infection in cystic fibrosis patients. J Cyst Fibros 2003;2:29–34.

[20] Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. *Pseudomonas aeruginosa* and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91–100.

[21] Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, et al. Initial *Pseudomonas aeruginosa* treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012;47:125–34.

[22] Mauch RM, Levy CE. Serum antibodies to *Pseudomonas aeruginosa* in cystic fibrosis as a diagnostic tool: a systematic review. J Cyst Fibros 2014;13:497–505.

[23] Pedersen SS, Espersen F, Hoiby N. Diagnosis of chronic *Pseudomonas aeruginosa* infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol 1987;25:1830–6.

[24] Kappler M, Kraxner A, Reinhardt D, Ganster B, Griese M, Lang T. Diagnostic and prognostic value of serum antibodies against *Pseudomonas aeruginosa* in cystic fibrosis. Thorax 2006;61:684–8.

[25] Brett MM, Ghoneim ATM, Littlewood JM. Serum antibodies to *Pseudomonas aeruginosa* in cystic fibrosis. Arch Dis Child 1986;61:1114–20.

[26] Farrell PM, Govan JR. Pseudomonas serology: confusion, controversy, and challenges. Thorax 2006;61:645–7.

[27] da Silva Filho LV, Tateno AF, Martins KM, Azzuz Chernishev AC, Garcia Dde O, Haug M, et al. The combination of PCR and serology increases the diagnosis of *Pseudomonas aeruginosa* colonization/infection in cystic fibrosis. Pediatr Pulmonol 2007;42:938–44.

[28] Tramper-Stranders GA, van der Ent CK, Slieker MG, Terheggen-Lagro SW, Teding van Berkhout F, Kimpen JL, et al. Diagnostic value of serological tests against *Pseudomonas aeruginosa* in a large cystic fibrosis population. Thorax 2006;61:689–93.

[29] Hayes Jr D, Farrell PM, Li Z, West SE. *Pseudomonas aeruginosa* serological analysis in young children with cystic fibrosis diagnosed through newborn screening. Pediatr Pulmonol 2010;45:55–61.

[30] Ratjen F, Walter H, Haug M, Meisner C, Grasemann H, Doring G. Diagnostic value of serum antibodies in early *Pseudomonas aeruginosa* infection in cystic fibrosis patients. Pediatr Pulmonol 2007;42:249–55.

[31] West SE, Zeng L, Lee BL, Kosorok MR, Laxova A, Rock MJ, et al. Respiratory infections with *Pseudomonas aeruginosa* in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002;287:2958–67.

[32] Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, et al. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol 2010;45:934–44.

[33] Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4–S14.

[34] Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey BW, Morgan W, et al. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros 2012;11:446–53.

[35] Wang X, Dockery DW, Wypij D, Fay ME, Ferris Jr BG. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15: 75–88.

[36] Zemanick E, Emerson J, Thompson V, McNamara S, Morgan W, Gibson R, et al. Clinical outcomes after initial Pseudomonas acquisition in cystic fibrosis. Pediatr Pulmonol 2014 Mar 18 [Epub ahead of print].

[37] Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, et al. *Pseudomonas aeruginosa* serology and risk for re-isolation in the EPIC trial. J Cyst Fibros 2013;12:147–53.

[38] Pressler T, Karpati F, Granstrom M, Knudsen PR, Lindblad A, Hjelte L, et al. Diagnostic significance of measurements of specific IgG antibodies to *Pseudomonas aeruginosa* by three different serological methods. J Cyst Fibros 2009;8:37–42.

[39] Pressler T, Kronborg G, Shand GH, Mansa B, Hoiby N. Determination of IgG subclass antibodies to *Pseudomonas aeruginosa* outer membrane proteins in cystic fibrosis lung infection using immunoblotting and enzyme-linked immunosorbent assay. Med Microbiol Immunol 1992;181: 339–49.

[40] Fomsgaard A, Dinesen B, Shand GH, Pressler T, Hoiby N. Antilipopolysaccharide antibodies and differential diagnosis of chronic *Pseudomonas aeruginosa* lung infection in cystic fibrosis. J Clin Microbiol 1989;27:1222–9.

[41] Pressler T, Pedersen SS, Espersen F, Hoiby N, Koch C. IgG subclass antibodies to *Pseudomonas aeruginosa* in sera from patients with chronic *Ps. aeruginosa* infection investigated by ELISA. Clin Exp Immunol 1990;81:428–34.

[42] van Ewijk BE, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK. High *Pseudomonas aeruginosa* acquisition rate in CF. Thorax 2006;61:641–2.

[43] Aanaes K, Johanse HK, Poulsen SS, Pressler T, Buchwald C, Hoiby N. Secretory IgA as a diagnostic tool for *Pseudomonas aeruginosa* respiratory colonization. J Cyst Fibros 2013;12:81–7.

[44] Campodonico VL, Llosa NJ, Grout M, Doring G, Maira-Litran T, Pier GB. Evaluation of flagella and flagellin of *Pseudomonas aeruginosa* as vaccines. Infect Immun 2010;78:746–55.

[45] Nelson JW, Govan JRW, Barclay GR. *Pseudomonas aeruginosa* flagellar antibodies in serum, saliva and sputum from patients with cystic fibrosis. Serodiagn Immunother Infect Dis 1990;4:351–61.

[46] Green DM, McDougal KE, Blackman SM, Sosnay PR, Henderson LB, Naughton KM, et al. Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients. Respir Res 2010;11:140.